Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

Completed · Early Phase 1

Conditions studied: Glioblastoma, Brain Metastases

In brief

This is two parallel studies to examine pharmacokinetic (PK), pharmacodynamic (PD), and pharmacogenetic (PG) endpoints following short-interval therapy (10-14) daily doses without dose reduction and interruption) with the ALK (anaplastic lymphoma kinase) small-molecule inhibitor, ceritinib. The Phase 0 study will investigate: 1. first recurrence GBM patients and 2. patients with CNS metastases from solid tumors such as, but not limited to, NSCLC (non-small cell lung cancer) and melanoma. The CNS (central nervous system) metastases Phase 0 is designed to identify PK effects (in addition to PD, and PG effects on ALK-positive NSCLC metastases), while the GBM Phase 0 is designed to identify PK, PD, and PG effects in all patients.

Key facts

Study ID

NCT02605746

Run by

St. Joseph's Hospital and Medical Center, Phoenix

People needed

10

Starts

2016-02-17

Expected to finish

2019-07-12

Last updated by the study team

2020-12-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• One prior resection of GBM or MRI evidence of solid tumor CNS metastasis
• All GBM and NSLC metastases must be ALK+
• Eastern Cooperative Oncology Group performance status ≤2
• Archival tumor tissue block available for research use
• Ability to understand written informed consent
• Recovery from toxicities related to prior anticancer therapies to ≤ grade 2 (CTCAE v 4.03). Exception: patients with any grade alopecia
• The following lab criteria are met:
• Absolute neutrophil count ≥ 1.5 x 10(9th power)/L
• Hemoglobin ≥ 8 g/dL
• Platelets ≥ 75 x 10(9th power)/L
• Serum total bilirubin ≤ 1.5 x upper limit of normal(ULN), except for patients with Gilbert's syndrome who may be included if total bilirubin ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN
• Aspartate transaminase (AST) < 3.0 x ULN, except for patients with liver metastasis, who are only included if AST < 5 x ULN; alanine transaminase (ALT) < 3.0 x ULN, except for patients with liver metastasis, who are only included if ALT < 5 x ULN
• Creatinine clearance ≥ 30 mL/min
• Patient has following lab values or has lab values corrected with supplements to be within normal limits at screening:
• Potassium ≥ LLN
• Magnesium ≥ LLN
• Phosphorus ≥ LLN
• Total calcium (corrected for serum albumin) ≥ LLN

You may not qualify if…

• Co-morbid condition(s) that prevent safe surgical treatment
• Active infection or fever > 38.5°C
• Patients with known hypersensitivity to any excipients of ceritinib
• Prior therapy with ceritinib
• Patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and clinically significant radiation pneumonitis (affecting activities of daily living or requiring therapeutic intervention)
• Clinically significant uncontrolled heart disease and/or recent cardiac event (within 6 months), such as:
• history of documented congestive heart failure (New York Heart Association functional classification III-IV);
• uncontrolled hypertension defined by a Systolic Blood Pressure ≥ 160 mm Hg and/or Diastolic Blood Pressure ≥ 100 mm Hg, with or without antihypertensive medication
• initiation or adjustment of antihypertensive medication(s) is allowed prior to screening;
• ventricular arrhythmias; supraventricular and nodal arrhythmias not controlled with medication;
• other cardiac arrhythmia not controlled with medication;
• corrected QTc > 450 msec using Fridericia correction on the screening ECG
• Impaired GI function or GI disease that may alter absorption of ceritinib or inability to swallow up to five ceritinib capsules daily
• Ongoing GI adverse events > grade 2 (e.g. nausea, vomiting, or diarrhea) at the start of the study
• Receiving medications that meet 1 of the following criteria and cannot be discontinued at least 1 week prior to start of treatment with ceritinib and for the duration of participation:
• Medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes
• Strong inhibitors or strong inducers of CYP3A4/5
• Medications with a low therapeutic index that are primarily metabolized by CYP3A4/5, CYP2C8 and/or CYP2C9
• Therapeutic doses of warfarin sodium (Coumadin) or any other coumadin-derived anti-coagulant. Anticoagulants not derived from warfarin are allowed
• Pregnant or nursing (lactating) women.
• Women of child-bearing potential, unless they are using highly effective methods of contraception during dosing and for 3 months after the last dose of study treatment.

Where it is running

• Barrow Brain and Spine — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.